Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 241 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results... March 27, 2023 Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... November 12, 2021 How Alcohol Increases Your Cancer Risk and What to Know About... August 29, 2023 Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support... September 21, 2020 Load more HOT NEWS ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After... ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and... 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective Datopotamab Deruxtecan Shows Promising Activity in Heavily Pretreated Advanced HR-positive/HER2-negative and...
